Rockville, Md. – October 12, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will host a three-hour investor event on October 20, 2026 to review its wet age-related macular degeneration (wet AMD) gene therapy program, with topline pivotal data anticipated in the fourth quarter of 2026.

Event runs 1:00 p.m. to 4:00 p.m. ET in New York and online

The session will be held in person in New York and streamed by webcast. It will cover the clinical program for surabgene lomparvovec (sura-vec, ABBV-RGX-314), which REGENXBIO is developing in collaboration with AbbVie.